Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis

Table 3 Linear regression analysis of S100A8 in 138 rheumatoid arthritis (RA) patients

Variable	β	SE	t	Pvalue	95% Confidence interval
Univariate analysis:
ACPA	2.23	0.27	8.34	< 0.001	1.70 to 2.76
Age	-0.03	0.01	-2.15	0.03	-0.06 to -0.002
RF	2.21	0.26	8.33	< 0.001	1.68 to 2.73
Carriage of HLA-DRB1*0401	1.05	0.32	3.26	0.001	0.41–1.69
Carriage of RAGE 82S	0.83	0.40	2.07	0.04	0.04 to 1.62
Carriage of shared epitope	0.94	0.36	2.63	0.01	0.23 to 1.66
Joint space narrowing^a	0.27	0.12	2.31	0.02	0.04 to 0.50
S100A9^a	0.48	0.13	3.65	< 0.001	0.22 to 0.75
S100A12^a	0.67	0.16	4.23	< 0.001	0.36 to 0.99
sRAGE^a	-0.77	0.31	-2.51	0.01	-1.37 to -016
Multivariate analysis:
RF	1.45	0.28	5.12	< 0.001	0.89 to 2.01
ACPA	1.22	0.29	4.24	< 0.001	0.65 to 1.79
S100A9^a	0.34	0.10	3.42	0.001	0.14 to 0.54

Adjusted R² of the multiple linear regression model = 0.49.
^aLogarithmic (base e) transformation.
ACPA, anti-citrullinated peptide antibodies; HLA, human leukocyte antigen; RF, rheumatoid factor; (s)RAGE, (soluble) receptor for advanced glycation end products.

ISSN: 1478-6362